Hormonal Therapy in Prostate Cancer - prIME Oncology
Expert Perspectives
Expert Perspectives

Hormonal Therapy in Prostate Cancer

Improving Disease Outcomes in Metastatic and Nonmetastatic Disease

Not a member of My prIME? Join now for instant access.

These Expert Perspectives are related to and given by the presenters of the 2018 Genitourinary Cancers Symposium.

Enhance your understanding of emerging trends and recent clinical trial data on hormonal therapy for prostate cancer with expert videos and downloadable slides.

A variety of topics are covered, including current and emerging treatment options for castration-resistant prostate cancer (CRPC), the use of newer hormonal therapies in hormone-sensitive disease and nonmetastatic prostate cancer, and safety concerns associated with these newer agents.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

0.5 AMA PRA Category 1 Credit

Release Date

Release Date

Mar 9, 2018

Expiration Date

Mar 10, 2019

Introduction
Tomasz Beer, MD

Endocrine options for CRPC
Joaquim Bellmunt, MD, PhD

Developments in treating hormone-sensitive disease: Progress at last
Axel Heidenreich, MD, PhD

Focus on safety issues of newer hormonal therapies
Celestia Higano, MD, FACP

prIME Points™
Tomasz Beer, MD

  • Tomasz Beer, MD, FACP Oregon Health & Sciences University
    Portland, Oregon, United States
  • Joaquim Bellmunt, MD, PhDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Axel Heidenreich, MD, PhDUniversitätsklinikum Köln
    Cologne, Germany
  • Celestia S. Higano, MD, FACPUniversity of Washington
    Seattle, Washington, United States

This educational activity is specifically designed to meet the needs of medical oncologists, urologists, and other healthcare professionals involved in the treatment of patients with prostate cancer.

After successful completion of this educational activity, participants should be able to:

  • Analyze clinical trial data on the efficacy and safety of current and emerging antagonists and inhibitors of androgen-receptor signaling in the treatment of nonmetastatic and hormone-sensitive metastatic prostate cancer
  • Implement treatment strategies for metastatic prostate cancer that sequence these newer endocrine options earlier in the clinical course of prostate cancer
  • Describe optimal approaches to manage treatment-related adverse events associated with hormonal therapeutic options for prostate cancer that can help maintain quality of life and adherence to treatment

This educational activity is supported by a grant from Astellas and Medivation, Inc., a Pfizer company.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Hormonal Therapy in Prostate Cancer - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Bellmunt has disclosed consulting fees from AstraZeneca, Merck, Pfizer, and Roche-Genentech. He has also disclosed independent contracting for Novartis Oncology and Sanofi. He has also received fees for membership on advisory committees or review panels from AstraZeneca, Genentech, Merck, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Higano has disclosed her role as University of Washington PI for clinical research trials with Aragon, Astellas, AstraZeneca, Bayer, Emergent, Hoffman LaRoche, Medivation, and Pfizer. She has also received fees for membership on advisory committees or review panels from Astellas, Bayer, Blue Earth, Clovis Oncology, Myriad, Orion, Pfizer, and Tolmar. She also disclosed her spouse receives salary from and is in a management position for CTI BioPharma. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Beer has disclosed consulting fees from AbbVie, AstraZeneca, Clovis Oncology, Janssen Biotech, Janssen Japan, and Pfizer. He has also disclosed that he has ownership interest in Salarius Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Heidenreich has disclosed consulting fees from Amgen, Astellas, Pfizer, Sanofi, and Takeda. He has also disclosed that he has received honoraria for promotional speaker’s bureaus from Amgen, Astellas, Pfizer, Sanofi, and Takeda. Has has also disclosed independent contracting for Amgen, Astellas, and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Amy Furedy RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.